Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyVentura County Mifepristone Coverage Update | Open…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Cushing's - Mifepristone Care Value Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of mifepristone products used to control hyperglycemia caused by endogenous Cushing's syndrome in adults with type 2 diabetes or glucose intolerance. It establishes preferred-product access, non-preferred-product prior authorization and exception requirements, documentation expectations, and a one-year approval duration.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCushing's - Mifepristone Care Value Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJuly 15, 2024
    Last ReviewApr 24, 2024
    Next Review DateN/A
    Key ActionFor a Korlym exception, the patient must have tried generic mifepristone tablets before requesting the exception.
    SourceLink
    POLICY UPDATE CHANGES

    This document establishes a new Cushing's mifepristone Care Value Policy effective July 15, 2024.

    1 yearApproval duration
    No PAPreferred product access
    PA requiredNon-preferred product
    AdultsCovered population

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Korlym exception criteria

    Korlym exception requests are covered when both A and B are met.

    Both A and B required

    • A. Standard criteria: Patient meets the standard Cushing's - Mifepristone Prior Authorization Policy criteria.

      The standard criteria are referenced but not reproduced in this document.

    • B. Product-specific exception requirements

      • i. Prior generic trial: Patient has tried generic mifepristone tablets.
      • ii. Inability to continue generic therapy: Patient cannot continue to use generic mifepristone tablets due to a formulation difference in inactive ingredient(s), such as dyes, fillers, or preservatives, which, per the prescriber, would result in a significant allergy or serious adverse reaction.

        Documentation required.

    Mifepristone is not covered for treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome. Its covered use under this policy is limited to controlling hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome.

    Provider Actions and Requirements

    Prior Authorization

    Non-Preferred Product Prior Authorization Required

    The Non-Preferred Product requires prior authorization under the standard Cushing's–Mifepristone Prior Authorization Policy criteria. Requests for the Preferred Product do not have to meet the standard prior authorization criteria.

    Prior Authorization

    Korlym Exception Requirements

    A Korlym exception request is approved only when the patient meets the standard Cushing's–Mifepristone Prior Authorization Policy criteria and meets both Korlym exception requirements: a prior trial of generic mifepristone tablets and inability to continue generic therapy because of an inactive-ingredient formulation difference that would cause a significant allergy or serious adverse reaction.

    Step Therapy

    Generic Mifepristone Trial Required

    Before a Korlym exception request, the patient must have tried generic mifepristone tablets.

    Documentation Required

    Required Supporting Documentation

    Submit supporting documentation when the criteria indicate that documentation is required. Acceptable records may include chart notes, prescription claims records, prescription receipts, and/or other relevant information.

    • Documentation is required where identified in the criteria.
    • Approvals are provided for 1 year in duration.
    Documentation Required

    Formulation-Related Exception Documentation

    The prescriber must document that the patient cannot continue generic mifepristone tablets because of a formulation difference in inactive ingredient(s)—such as dyes, fillers, or preservatives—that would result in a significant allergy or serious adverse reaction.

    Denial Risk

    Do Not Use for Unrelated Type 2 Diabetes

    Mifepristone should not be used to treat type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.

    Denial Risk

    Non-Preferred Product Criteria Not Met

    A Non-Preferred Product request does not meet coverage requirements when the standard Cushing's–Mifepristone Prior Authorization Policy criteria are not satisfied. A Korlym exception request does not meet requirements when the standard criteria are not met or when either the required generic mifepristone trial or the documented formulation-related exception requirement is absent.

    Clinical Background

    Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance. The policy addresses use when surgery has failed or the patient is not a candidate for surgery.

    Definitions

    Endogenous Cushing's syndrome
    DisorderA disorder characterized by endogenous hypercortisolism.
    Relevant populationAdults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
    Clinical contextMifepristone is indicated when surgery has failed or the patient is not a candidate for surgery.
    Hypercortisolism
    DefinitionExcess cortisol activity associated with endogenous Cushing's syndrome.
    Resulting conditionHypercortisolism can cause hyperglycemia.
    Mifepristone useMifepristone is indicated to control hyperglycemia secondary to hypercortisolism.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCushing's - Mifepristone Care Value Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJuly 15, 2024
    Last ReviewApr 24, 2024
    Next Review DateN/A
    Key ActionFor a Korlym exception, the patient must have tried generic mifepristone tablets before requesting the exception.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsClinical BackgroundDefinitions